OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
|Articles|May 18, 2022
Daily Medication Pearl: Simeprevir (Olysio)
Author(s)Saro Arakelians, PharmD
:Simeprevir (Olysio) is an NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen.
Advertisement
Medication Pearl of the Day: Simeprevir (Olysio)
Indication: Simeprevir (Olysio) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
Insight:
- Dosing:One capsule taken once daily with food.
- Dosage forms: Capsule 150 mg.
- Adverse events: The most common reported adverse reactions (greater than 20% of subjects) in subjects receiving the combination of simeprevir with peginterferon and ribavirin and occurring with at least 3% higher frequency compared to subjects receiving placebo in combination with peginterferon alfa and ribavirin during the first 12 weeks of treatment were rash (including photosensitivity), pruritus, and nausea.
- Mechanism of action: Simeprevir is an inhibitor of the HCV NS3/4A protease, which is essential for viral replication. In a biochemical assay, simeprevir inhibited the proteolytic activity of recombinant genotype 1a and 1b HCV NS3/4A proteases, with median Ki values of 0.5 nM and 1.4 nM, respectively.
- Manufacturer: Janssen Therapeutics
Source
Advertisement
Related to this article
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar with it and with the potential risks.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
5